Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Merck_&_Co.
|
| gptkbp:acquisitionYear |
2014
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:defunct |
2014
|
| gptkbp:focus |
antiviral drugs
HIV treatments hepatitis C treatments |
| gptkbp:foundedIn |
1998
|
| gptkbp:founder |
gptkb:Jean-Pierre_Sommadossi
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Idenix Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:IDX184
gptkb:Samatasvir gptkb:Sofosbuvir_(development) gptkb:Valopicitabine |
| gptkbp:parentCompany |
gptkb:Merck_&_Co.
|
| gptkbp:status |
defunct
|
| gptkbp:stockSymbol |
gptkb:IDIX
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:bfsParent |
gptkb:Jean-Pierre_Sommadossi
|
| gptkbp:bfsLayer |
7
|